Skip to content

Abnormal Circulating Insulin Like Growth Factor Binding Protein Acid Labile Subunit Concentration C4476922

Published: July 22, 2026Updated: August 20, 2026

Abnormal levels of a protein that helps transport growth factors in the blood. Can affect growth and metabolism. Typically evaluated by hormone specialists.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
E34.9
ICD-11
5A00.0
Body system
endocrine
Severity
moderate
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Pseudotumor cerebri-like symptoms

Symptoms mimicking increased intracranial pressure including severe headache, vision changes, and papilledema.

This is a medical emergency. Seek immediate emergency care if experiencing severe headache, vision loss, double vision, or vomiting.

Growth failure in children

(constitutional)

Delayed or slowed growth velocity in height and weight compared to peers of the same age and gender.

Frequency: 70-80% of pediatric patients

Fatigue

(constitutional)

Persistent feeling of tiredness, weakness, or lack of energy that interferes with daily activities.

Frequency: 60-70% of patients

Short stature

(endocrine)

Height significantly below the expected range for age, sex, and genetic background.

Frequency: 50-60% of affected children

Insulin resistance

(endocrine)

Reduced cellular response to insulin leading to elevated blood glucose and compensatory hyperinsulinemia.

Frequency: 40-50% of patients

Delayed puberty

(endocrine)

Absence of secondary sexual characteristics beyond the expected age range, including lack of testicular enlargement in males or breast development in females.

Frequency: 35-45% of adolescent patients

Decreased bone mineral density

(musculoskeletal)

Reduced bone mass and density increasing risk of fractures and osteopenia.

Frequency: 20-30% of patients

Headache

(neurologic)

Recurrent or persistent head pain that may vary in intensity, location, and duration.

Frequency: 15-25% of patients

Abnormal lipid profile

(metabolic)

Elevated triglycerides, altered LDL cholesterol, or reduced HDL cholesterol levels.

Frequency: 15-25% of patients

Hypertension

(cardiovascular)

Elevated blood pressure consistently above normal ranges, potentially related to metabolic and endocrine disturbances.

Frequency: 5-10% of patients

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Endocrine management

Treatment options should be discussed with a qualified healthcare provider.

lifestyle
2

Growth Hormone Replacement Therapy

Endocrine evaluation to assess growth hormone-IGF axis function. If GH deficiency is confirmed, recombinant growth hormone therapy may be initiated under specialist supervision to normalize IGFALS levels and support normal growth and metabolism.

medication
3

Endocrine Specialist Monitoring

Regular assessment of IGFALS, IGF-1, and growth parameters through an endocrinology specialist. Serial laboratory testing helps track natural disease course and treatment response over time.

monitoring

Additional treatment options

Nutritional Optimization

Ensure adequate protein intake and balanced nutrition to support endogenous IGF production. Avoid severe caloric restriction which can suppress IGF axis function.

lifestyle

Sleep Optimization

Adequate sleep hygiene supports natural growth hormone secretion which occurs primarily during deep sleep phases. Target 8-10 hours for children and 7-9 hours for adults.

complementary

When to seek medical help

Recognize when you need immediate medical attention.

Schedule an appointment soon

Symptoms associated with this condition. Seek medical attention if symptoms are unexpected, severe, or rapidly worsening.- Contact your healthcare provider if symptoms persist or worsen. Seek emergency care for sudden severe symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Abnormal Circulating Insulin Like Growth Factor Binding Protein Acid Labile Subunit Concentration C4476922?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Baxter RC. Insulin-like growth factor binding protein-3 (IGFBP-3): Novel ligands reveal unusual actions within the circulation. Growth Horm IGF Res. 2020.

review2020
2

Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 2002.

review2002
3

Domene HM, Bengolea SV, Martinez AS, et al. Deficiency of the acid-labile subunit of the IGF ternary complex: phenotypic effects during childhood and adolescence. J Clin Endocrinol Metab. 2004.

clinical_trial2004
4

Hwa V, Haeusler G, Pratt KL, et al. Total deficiency of the acid-labile subunit (ALS) results in severe short stature. J Clin Endocrinol Metab. 2006.

clinical_trial2006
5

Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011.

guideline2011
6

Jone L, Tapanainen J, Savage MO, Burren CP. The IGF system in disorders of growth and puberty. Ann Endocrinol (Paris). 2005.

review2005
7

Melmed S, Polonsky KS, Larsen PR, Kronenberg HM. Williams Textbook of Endocrinology. 14th ed. Elsevier; 2019.

textbook2019
8

Savage MO, Burren CP, Rosenfeld RG. The IGF system and disorders of growth. Endocr Dev. 2007.

review2007

Medication Comparisons

Compare medications used to treat Abnormal Circulating Insulin Like Growth Factor Binding Protein Acid Labile Subunit Concentration C4476922. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy